We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Healthcare Ent. | HCEG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 20.50 |
| Top Posts |
|---|
Posted at 24/2/2011 10:11 by willib2 fft.Where on earth are you posting from. Hope you dont have a heart condition while awaiting a reply. HCEG had a couple of consolidations, and considerably more huge write offs. In fact the write offs were MASSIVELY more than any turnover they ever achieved. If ever there was a reason for AIM to tighten the rules, this was one of them. They supposedly had the best management team ever and for many tears this thread was entertained by a vibrant group of supposed knowledgeable investors who couldnt see the wood for the trees. Needless to say the person who touted it most suddenly vanished, a salutory lesson to any investor. You could possibly use it against CGT on other positive share dealings, but you would have to check that out. |
Posted at 18/2/2011 17:26 by mark30 aye go ahead, try talking to them ! they have tissues to wipe investors off their feet!aint that the troof willie lad |
Posted at 07/4/2010 08:10 by pre back up towards 80p from here now?? Wow!!Fertiligent medical device receives FDA approval TIDMHCEG RNS Number : 7916J Healthcare Enterprise Group PLC 07 April 2010 ? 07 April 2010 Healthcare Enterprise Group PLC (AIM: HCEG) ("Healthcare Enterprise" or the "Group") Fertiligent medical device receives FDA approval Healthcare Enterprise, an international healthcare group, is pleased to announce that Reproductive Sciences Limited ("RSL" or "the Company"), in which it holds a 27% interest, has reported that its Fertiligent artificial insemination device has received formal approval from the US Food and Drugs Administration ("FDA") for its sale in the United States. Highlights: · FDA approval received · European CE approval for the final model received in March 2010 · Manufacturing & assembly agreement signed with Catheter Research, Inc of Indianapolis, Indiana, USA · Discussions underway to appoint US and international distributors with the aim of commencing sales later in 2010 RSL holds the worldwide sales and marketing rights to Fertiligent's products, including the "Evie" device. HCEG has contributed management oversight to RSL, with direct private investment from funders including Nigel Wray. RSL has focussed on Fertiligent's "Evie" product, a high quality, low cost intrauterine sperm pump to help assist infertile couples conceive. From initial trials conducted in Germany and Israel, Fertiligent offers infertile couples an enhanced intrauterine insemination success rate and the chance of avoiding invasive and costly artificial reproductive techniques such as in vitro fertilisation. The Company, RSL, owns 45% of the issued capital in the Israeli Fertiligent Limited company, with options to increase that holding to 78% of the fully diluted capital. RSL also owns the exclusive, worldwide sales & marketing rights to the Israeli Fertiligent company's products. Lyndon Gaborit, Executive Deputy Chairman of Healthcare Enterprise, commented: "We are delighted that this critical milestone has been achieved for the Fertiligent 'Evie' medical device. FDA approval, and the recently received CE approval for the final production version, significantly reduces risk and paves the way for a roll out of this exciting product around the world. Women's reproductive health is a significant and increasing market and this new product, which provides couples with a low cost alternative to existing reproduction methods such as IVF, should, we believe, find good market acceptance with associated returns to RSL's investors, including HCEG." For further information, please contact: +------------------- | Healthcare Enterprise Group PLC | | | | Lyndon Gaborit | Tel: +44 (0)20 7680 | | | | 3649 | | +------------------- | Daniel Stewart & Company plc | Tel + 44 (0)20 7776 6550 | | Andrew Edwards/Emma Earl | | | | | +------------------- | Bishopsgate Communications | | | | Robyn Samuelson / Giang Nguyen | Tel: +44 (0)20 7562 | | | | 3355 | | | | | | +------------------- Note to Editors Healthcare Enterprise Healthcare Enterprise Group PLC (HCEG) is a healthcare investment group which invests in synergistic products and services within the healthcare industry. It currently has two main investments: · Ebiox Limited - Patented decontamination and disinfectant products that are safe and alcohol free but substantially more effective than conventional methods at destroying embedded microorganisms. The Ebiox range includes hand hygiene products, surface disinfectants and products to clean and decontaminate surgical instruments. HCEG owns 20% of Ebiox Limited. · Reproductive Sciences Limited - Innovative slow release pump for intrauterine insemination, proven to significantly enhance pregnancy success rates. HCEG owns 27% of the Company. This information is provided by RNS The company news service from the London Stock Exchange END MSCUGUUWCUPUGBQ |
Posted at 10/2/2010 16:50 by willib2 Mark30You keep looking at Hceg, and yes I know you miss the old banter. I'm not trawling though, remember I am a substantial Pace investor, so naturally I look all the time, and I know whats going on. However you are one up on me at the moment as I havent top sliced. |
Posted at 09/2/2010 11:15 by 123michelle Any one interested in listening to John Honey talk about Healthcare Enterprise Group at a small investor seminar in London on Wednesday 10th February? Free drinks after in the pub and a chance to collar him for some questions. My email is michelle.levin@t1ps. |
Posted at 26/11/2009 08:21 by rheiner Latest bit of news - quite good for a change :-26 November 2009 Healthcare Enterprise Group PLC ("Healthcare Enterprise" or the "Group") Ebiox announces sales growth of 53% in Q3 and launch of new products Healthcare Enterprise (AIM: HCEG), an international healthcare group, is pleased to announce that Ebiox Limited, in which it holds a 20% interest, has reported sales growth of 53% in the three months to September 2009, as compared to the same period last year, following a GBP800,000 cash injection by private investors, including Nigel Wray. The July to September 09 quarter was the first under Ebiox' new management, headed by John Honey, formerly Senior VP at Reckitt Benckiser plc. Highlights: * Sales up 53% on the same period last year following revenue growth of hand & surface cleaning products * Launch of new biodegradable, macerator-friendly, hard surface antimicrobial wipe * Pipeline of new products includes a non alcohol-based sanitising foam hand rub The new Trionic D biodegradable wipes contain the same proven Ebiox Trionic formulation to clean and disinfect medical devices and hard surfaces, removing biofilms and providing a broad efficacy in removing and killing harmful pathogens. They use a high wet strength cellulose fibre sheet which is fully biodegradable and can be disposed of after use through a macerator unit within a Hospital sluice room thus avoiding the need to dispose of within a clinical waste stream. Great Ormond Street Hospital has just completed a successful six month trial of the disinfectant wipes and Ebiox is currently engaged in discussions with other potential customers, while also seeking to extend the use of the Ebiox Trionic formulation to other healthcare and hygiene applications. Ebiox Esense is a non alcohol based hand rub. The product has a broad range antimicrobial efficacy and is fully compliant to the required European efficacy standards for hygienic hand rubs used in medical environments. The formulation is also Chlorhexidine and Triclosan free and encourages frequent use so as to protect users against potential cross contamination issues and as a defense in many situations arising from public places. Lyndon Gaborit, Executive Deputy Chairman of Healthcare Enterprise, commented: "We are delighted with the sales growth announced by Ebiox today. Whilst we have seen some increased demand as a result of concerns about swine flu, Ebiox has under its dedicated new management and with additional funding, displayed strong growth and is developing a solid pipeline of new products." |
Posted at 18/3/2009 18:04 by sandy1888 Healthcare group has a month to find investment Healthcare Enterprise Group, the Warrington-based healthcare product group that includes occupational healthcare and first aid operator Crest Medical, has warned that it may be unable to continue trading unless it secures investment in the next month. The group suspended trading of its shares on AIM in December after announcing it would not be able to publish its annual report and preliminary results in accordance with AIM rules. Since then it has raised £260,500 before expenses after selling almost 10 per cent of its holding in First Aid Holdings, but efforts to secure further investment have so far proved unsuccessful. However, it confirmed that it was still in talks with a small group of investors and is considering options to sell shares in investee companies |
Posted at 06/2/2009 08:14 by willib2 Goldpot.Just how good an investor are you. Whats the point of giving it a week, it already is f++++d. Me and my friend Substp are just following its death throes. |
Posted at 18/9/2008 07:32 by philwill Life in the old dog yet :-)Appointment of Adviser/Placing/Trad RNS Number : 7066D Healthcare Enterprise Group PLC 18 September 2008 Healthcare Enterprise Group PLC Appointment of Adviser, share placing, issue of a convertible loan, disposal of shares in First Aid Holdings Ltd and trading update Healthcare Enterprise Group Plc ("HCEG", the "Company", or "the "Group") is pleased to announce the appointment of Daniel Stewart & Company Plc as Nominated Adviser and broker to the Company with immediate effect. Trading in the Company's shares, which was suspended on 18th August 2008 pending the appointment of a new nominated adviser, is expected to resume at 8:00 am today, 18 September 2008. The Company also announces that it has raised £400,000 (before expenses) by the issue of 100,000,000 new ordinary shares at 0.3 pence ("Placing") Application has been made for the admission of the new ordinary shares to trading on AIM, which is expected to be effective on 25 September 2008. The Company has also issued a convertible loan of £100,000, due in six months and convertible subject to shareholder approval at 0.3p per ordinary HCEG share (interest at 12% p.a. will only be payable if the loan is not converted). John Gunn, a director of the Company, has agreed to subscribe for 16,666,667 Ordinary Shares in the Placing. Following completion of the Placing, he will have an interest in 41,140,581 Ordinary Shares representing approximately 9.37 per cent. of the then issued share capital of the Company. The directors, other than Mr Gunn, consider, having consulted with the Company's Nominated Adviser, that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned. The Company has also sold 218,750 shares (9.8 per cent.) in First Aid Holdings Limited ("FAH") for a consideration of £437,500 ("Disposal"), in order to provide working capital for the Group and to settle certain liabilities assumed under the sale agreement of the Group's former wholly owned subsidiary, Crest Medical Limited. The Group retains a 34.3 per cent. shareholding in FAH. FAH and its subsidiaries are engaged in the sale and distribution of first aid and healthcare related products. Whilst the proceeds of the Placing and the Disposal provide short term working capital for the Group, until the end of 2008, it will need to raise further capital to meet its medium and longer term requirements. The Company is in advanced discussions with a small group of investors, already known to the Company, with a view to raising up to a further £2.25m ("Additional Placing"). These funds, if raised, will be used to finance the medium and long term development of the Company's businesses. This Additional Placing would require the approval of shareholders in General Meeting. Whilst the Directors are confident that the Additional Placing will proceed, there can be no guarantee that it will successful. Shareholders should note that in the event the Additional Placing does not proceed, there can be no certainty that the Company will be able to meet its financial commitments (assuming other sources of funding cannot be secured) in the medium to long term. The Company expects to finalise the Additional Placing within the next month and will make further announcements as appropriate. Proposed executive chairman of Ebiox Limited The Company is pleased to announce that John Honey (aged 53) has agreed to become Executive Chairman of its Ebiox Limited subsidiary. He has invested £100,000 pursuant to the Placing. John Honey brings a wealth of experience in the disinfectant and decontamination industry as well as senior management roles in marketing and general management. John previously served as Senior Vice President of Reckitt Benckiser plc, responsible at various times during his 29 year tenure as executive responsible for Reckitt's global cleaning and disinfectant businesses, including Dettol, Lysol and Cilit Bang brands and its worldwide over the counter business which included Boots Healthcare International (which was acquired for £1.9Bn). He retired from Reckitt's in 2007 to pursue private interests. John's main focus initially will be on overseeing the development and further commercialisation of the Ebiox range of disinfectant and decontamination products, and the appointment of a suitably qualified chief executive for that business. John will also advise on the appropriate marketing strategy for the roll out of Fertiligent's "Evie" brand slow release insemination device. Mr. Honey intends in due course to join the main board of the Company, at which time a further announcement will be made. Ebiox Further progress at Ebiox has been limited by a shortage of working capital and the hardening of supplier payment terms. Customers have been maintained although sales of Ebiox products have been affected. Synergy Healthcare Plc's acquisition of Vernon Carus Limited, Ebiox distributor to the NHS, will require a change in distributor due to product conflicts, and sales under the agreement with Sultan Healthcare Inc. have been below target due to general uncertainties and certain country specific requirements which necessitate additional testing and re-approvals for the 'Solo' branded range. Ebiox has focused on maintaining supplies to existing customers whilst reviewing the market opportunities and examining potential areas of expansion and market cooperation. Patents, registrations and trademarks have been selectively maintained (including in the USA) to allow the later roll out of the companies' products in different geographical territories. The Company has also reviewed its product offering and will, following the appointment of John Honey as Executive Chairman and other new management appointments, undertake product enhancements and further development which will be funded from the Placing proceeds. Reproductive Sciences Limited The Company is pleased to announce good progress in Reproductive Sciences Limited ("RSL"), which owns 19.8 per cent. of Fertiligent Limited, an Israeli company which has developed a slow release insemination device to improve the chance of conception. In previous trials the Fertiligent product recorded a 234% improvement in success rate against IUI (from 6.66% - 15.55%). Further larger studies in 100 patients are commencing in Haifa, Israel in September 2008 and additional trials of the product at The London Bridge Fertility, Gynaecology and Genetics Centre, London Bridge, London, UK are expected to commence later in September 2008. An application for registration of the product with the United States Food and Drug Administration (FDA) is presently underway with approval expected to be secured before the end of 2008. The Company has advanced $150,000 to Fertiligent by way of a convertible loan and intends to advance a further $100,000 under the same convertible loan agreement, payable from the Placing announced above. These funds, which will be used by Fertiligent for product trials and working capital, convert into 9.4% of the equity such that RSL will own 29.2% of Fertiligent with options to increase that holding to 71.7% for the payment of an additional $1.5 million approximately. The Company is in discussions with Fertiligent in relation to further capital required to commence the marketing of the product internationally. RSL's contribution will be funded from the Additional Placing mentioned above. |
Posted at 21/12/2007 09:40 by substp Although the fraudulent methods used to manipulate the market for highly speculative securities, especially low-priced securities, have changed over time, many of the basic schemes employed have remained fairly constant. One common practice involves the use of reporting shell companies in "pump-and-dump" schemes. This type of scheme generally involves misleading investors. These schemes typically have many of the following characteristics: the shell company has no or nominal assets and operations and a small trading market; the shell company promoters issue large amounts of securities to themselves or designated nominees, sometimes using Form S-8; the shell company acquires or is merged with a private business that the promoters claim has high growth potential; inadequate information is available to investors regarding the post-transaction company; the promoters "pump" up the price of the stock to investors through unduly positive press releases on the company and its prospects, exaggerated tout sheets, or fraudulent messages on the Internet;14 the promoters use high-pressure tactics to get people to invest, and also engage in market manipulation to create artificial demand and artificially high prices for the stock of the company; and the promoters "dump" their stock in the company by selling it at the artificially high prices their promotional activities have created, halt those activities and move on, allowing the price of the stock to sink in value in the hands of the investors who have been misled into purchasing it.15 Many investors have been victimized in variants of the basic shell company scheme over the years.16 And there is lots more..... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
